Who
Allene M. Diaz
Director
Company insider
Files Form 4 as: Director, Ionis Pharmaceuticals; Director, Mersana Therapeutics; Director, Allena Pharmaceuticals.
In numbers
- Trades disclosed
- 74
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $10.6M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 6 May 2019
- Last trade
- 7 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $476K10,111 at $47.11 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $864K10,111 at $85.42 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,111 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,111 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $476K10,111 at $47.11 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $864K10,111 at $85.42 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,369 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,301 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,369 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,301 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $424K10,321 at $41.08 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $457K12,000 at $38.06 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $721K18,000 at $40.05 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,321 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3.1M39,265 at $79.11 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M14,608 at $79.88 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $81K1,005 at $80.80 | filing |
| 3 Mar 2026filed 5 Mar 2026 | IONS Ionis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,000 at $0.00 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 1,357 Shares of StockIONS · dailypolitical.com · 20 Oct 2026Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)IONS · finanznachrichten.de · 16 Oct 2026Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewIONS · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Allene M. Diaz; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.